SECURITIES PURCHASE AGREEMENT By and Between ONCONOVA THERAPEUTICS, INC. and HANX BIOPHARMACEUTICALS, INC. Dated as of May 10, 2019Securities Purchase Agreement • August 14th, 2019 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 10, 2019 (the “Signing Date”), by and between Onconova Therapeutics, Inc., a Delaware corporation (the “Company”), and HanX Biopharmaceuticals, Inc., a limited liability company established under the laws of the People’s Republic of China (the “Purchaser”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. LICENSE AND COLLABORATION AGREEMENT DATED AS OF May 10, 2019 by...License and Collaboration Agreement • August 14th, 2019 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”), dated as of May 10, 2019 (the “Effective Date”), is made by and among Onconova Therapeutics, Inc., a Delaware corporation (“Onconova”), and HanX Biopharmaceuticals, Inc., a company registered under the laws of the People’s Republic of China, having its registered office at 688 Binan Road, Binjing District, Hangzhou, China 310051 (“HanX”). Onconova and HanX are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
